Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm Maclure

Showing results (61-70 of 105) with videos related to

Pageof 11
Sort By:
Pharmacoepidemiology and Drug Safety|June 18, 2020
Bias in case-crossover studies of medications due to persistent use: A simulation studyKatsiaryna Bykov, Shirley V Wang, Jesper Hallas, et al.
Clinical Therapeutics|July 22, 2008
Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medicationsColin R Dormuth, Malcolm Maclure, Robert J Glynn, et al.
BMJ Quality & Safety|October 16, 2024
Pragmatic randomised trial assessing the impact of peer comparison and therapeutic recommendations, including repetition, on antibiotic prescribing patterns of family physicians across British Columbia for uncomplicated lower urinary tract infectionsGreg Carney, Malcolm Maclure, David M Patrick, et al.
Clinical Pharmacology and Therapeutics|October 10, 2003
Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockersSebastian Schneeweiss, Stephen B Soumerai, Malcolm Maclure, et al.
Clinical Therapeutics|July 25, 2006
Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthmaColin R Dormuth, Robert J Glynn, Peter Neumann, et al.
The New England Journal of Medicine|March 15, 2002
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitorsSebastian Schneeweiss, Alexander M Walker, Robert J Glynn, et al.
Clinical Therapeutics|March 15, 2003
Physician gender and changes in drug prescribing after the implementation of reference pricing in British ColumbiaMargreet S Duetz, Sebastian Schneeweiss, Malcolm Maclure, et al.
The Cochrane Database of Systematic Reviews|August 6, 2010
Pharmaceutical policies: effects of restrictions on reimbursementCarolyn J Green, Malcolm Maclure, Patricia M Fortin, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|April 12, 2002
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilizationSebastian Schneeweiss, Stephen B Soumerai, Robert J Glynn, et al.
Epidemiology (Cambridge, Mass.)|May 18, 2011
Future cases as present controls to adjust for exposure trend bias in case-only studiesShirley Wang, Crystal Linkletter, Malcolm Maclure, et al.
Pageof 11

Showing results (61-70 of 105) with videos related to

Sort By:
Pageof 11
Pharmacoepidemiology and Drug Safety|June 18, 2020
Bias in case-crossover studies of medications due to persistent use: A simulation studyKatsiaryna Bykov, Shirley V Wang, Jesper Hallas, et al.
Clinical Therapeutics|July 22, 2008
Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medicationsColin R Dormuth, Malcolm Maclure, Robert J Glynn, et al.
BMJ Quality & Safety|October 16, 2024
Pragmatic randomised trial assessing the impact of peer comparison and therapeutic recommendations, including repetition, on antibiotic prescribing patterns of family physicians across British Columbia for uncomplicated lower urinary tract infectionsGreg Carney, Malcolm Maclure, David M Patrick, et al.
Clinical Pharmacology and Therapeutics|October 10, 2003
Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockersSebastian Schneeweiss, Stephen B Soumerai, Malcolm Maclure, et al.
Clinical Therapeutics|July 25, 2006
Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthmaColin R Dormuth, Robert J Glynn, Peter Neumann, et al.
The New England Journal of Medicine|March 15, 2002
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitorsSebastian Schneeweiss, Alexander M Walker, Robert J Glynn, et al.
Clinical Therapeutics|March 15, 2003
Physician gender and changes in drug prescribing after the implementation of reference pricing in British ColumbiaMargreet S Duetz, Sebastian Schneeweiss, Malcolm Maclure, et al.
The Cochrane Database of Systematic Reviews|August 6, 2010
Pharmaceutical policies: effects of restrictions on reimbursementCarolyn J Green, Malcolm Maclure, Patricia M Fortin, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|April 12, 2002
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilizationSebastian Schneeweiss, Stephen B Soumerai, Robert J Glynn, et al.
Epidemiology (Cambridge, Mass.)|May 18, 2011
Future cases as present controls to adjust for exposure trend bias in case-only studiesShirley Wang, Crystal Linkletter, Malcolm Maclure, et al.
Pageof 11